Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations

Author:

Baliakas Panagiotis1,Agathangelidis Andreas23,Hadzidimitriou Anastasia14,Sutton Lesley-Ann1,Minga Eva4,Tsanousa Athina5,Scarfò Lydia23,Davis Zadie6,Yan Xiao-Jie7,Shanafelt Tait8,Plevova Karla9,Sandberg Yorick10,Vojdeman Fie Juhl11,Boudjogra Myriam12,Tzenou Tatiana13,Chatzouli Maria14,Chu Charles C.7,Veronese Silvio15,Gardiner Anne6,Mansouri Larry1,Smedby Karin E.16,Pedersen Lone Bredo11,Moreno Denis17,Van Lom Kirsten18,Giudicelli Véronique17,Francova Hana Skuhrova9,Nguyen-Khac Florence19,Panagiotidis Panagiotis13,Juliusson Gunnar20,Angelis Lefteris5,Anagnostopoulos Achilles21,Lefranc Marie-Paule17,Facco Monica2223,Trentin Livio2223,Catherwood Mark24,Montillo Marco15,Geisler Christian H.11,Langerak Anton W.10,Pospisilova Sarka9,Chiorazzi Nicholas7,Oscier David6,Jelinek Diane F.25,Darzentas Nikos26,Belessi Chrysoula14,Davi Frederic19,Ghia Paolo23,Rosenquist Richard1,Stamatopoulos Kostas1421

Affiliation:

1. Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden;

2. Università Vita-Salute San Raffaele, Milan, Italy;

3. Division of Molecular Oncology and Department of Onco-Hematology, Istituto di Ricovero e Cura a Carattere Scientifico, San Raffaele Scientific Institute, Milan, Italy;

4. Institute of Applied Biosciences, Centre for Research and Technology-Hellas, Thessaloniki, Greece;

5. Department of Informatics, Aristotle University of Thessaloniki, Thessaloniki, Greece;

6. Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom;

7. The Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, Manhasset, NY;

8. Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN;

9. Central European Institute of Technology, Masaryk University and University Hospital Brno, Brno, Czech Republic;

10. Department of Immunology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands;

11. Department of Hematology, Rigshospitalet, Copenhagen, Denmark;

12. Hôpital Pitié-Salpêtrière, Service d'Hématologie Biologique, Paris, France;

13. First Department of Propaedeutic Medicine, University of Athens, Athens, Greece;

14. Hematology Department, Nikea General Hospital, Piraeus, Greece;

15. Molecular Pathology Unit and Haematology Department, Niguarda Cancer Center, Niguarda Ca’ Granda Hospital, Milan, Italy;

16. Department of Medicine, Solna, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden;

17. ImMunoGeneTics (IMGT), Université de Montpellier, Laboratoire d'Informatique Gaspard-Monge, Institut de Génétique Humaine, Montpellier, France;

18. Department of Hematology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands;

19. Hematology Department and University Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France;

20. Lund University and Hospital Department of Hematology, Lund Stem Cell Center, Lund, Sweden;

21. Hematology Department and Hematopoietic Cell Transplantation Unit, Georgios Papanicolaou Hospital, Thessaloniki, Greece;

22. Department of Medicine, Hematology and Clinical Immunology Branch, Padua University School of Medicine, Italy;

23. Venetian Institute of Molecular Medicine, Padova, Italy;

24. Department of Hemato-Oncology, Belfast City Hospital, Belfast, United Kingdom;

25. Department of Immunology, Mayo Clinic, Rochester, MN; and

26. Central European Institute of Technology, Masaryk University, Brno, Czech Republic

Abstract

Key Points CLL stereotyped subset #2 (IGHV3-21/IGLV3-21) is uniformly aggressive independently of somatic hypermutation status. The prognosis for non–subset #2/IGHV3-21 CLL resembles that of the remaining CLL cases with similar somatic hypermutation status.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3